Focused Ultrasound Thalamotomy for Essential Tremor

1.The Vim target and the pivotal trial

The target is the Vim nucleus, the thalamic relay of the cerebello-thalamo-cortical tremor network, contralateral to the dominant or more disabling hand. A single thermal lesion there interrupts the oscillatory circuit. The pivotal evidence is the sham-controlled randomized trial by Elias and colleagues (N Engl J Med, 2016): unilateral MRgFUS thalamotomy produced roughly a 47% improvement in hand-tremor score at 3 months versus essentially no change after sham, and the benefit was largely maintained at follow-up. On the strength of that trial the FDA approved Exablate Neuro for unilateral thalamotomy in medication-refractory essential tremor in July 2016 — the first approved transcranial focused-ultrasound brain treatment. Open-label cohorts have since shown that, while some tremor recurrence occurs, a clinically meaningful effect persists in the majority at 3 to 5 years.

Candidacy mirrors the historical thalamotomy/DBS population: moderate-to-severe essential tremor refractory to adequate trials of propranolol and primidone, disabling enough to justify a permanent lesion, in a patient who understands that the result is not adjustable. MRgFUS is the natural choice for a patient who is unwilling to accept implanted hardware, is a poor candidate for awake DBS, or is anticoagulated and cannot easily stop — provided the skull cooperates.

2.The second side: staged bilateral treatment

Thalamotomy was historically confined to one side because bilateral thalamic lesions carried an unacceptable risk of dysarthria and gait/balance impairment. That caution still governs practice. After accumulating safety data on staged second-side treatment, the FDA approved staged bilateral (contralateral, second-side) MRgFUS thalamotomy for essential tremor in 2022, performed as a separate session months after the first. The second side is offered selectively, with explicit counseling that bilateral thalamic lesioning raises the risk of speech and balance side effects above the unilateral baseline. The default for most patients remains a single, well-chosen side.

3.What SDR is, and why it decides eligibility

The skull is the single greatest obstacle to transcranial ultrasound. Bone absorbs and scatters acoustic energy, and a heterogeneous, thick, or porous skull defocuses the beam and dumps energy into the bone itself. The standard screening metric is the skull density ratio (SDR) — computed from a screening head CT as the ratio of the radiodensity of cortical bone to that of the diploic (marrow) layer, averaged across the elements of the array. A high SDR means a relatively uniform, dense skull that transmits energy efficiently; a low SDR means a spongy or irregular skull that wastes it.

SDR is predictive of how much temperature elevation a given patient's skull will permit, and it has therefore become a screening gate. The widely used working threshold in the United States is approximately SDR ≥ 0.40; historically the device screening excluded patients at or below roughly 0.45 ± 0.05, and many centers prefer ≥ 0.45 for a comfortable margin. Below the threshold, target temperature is harder to reach, sessions run longer, intraprocedural discomfort rises, and the risk of an inadequate lesion (treatment failure) climbs. A screening CT for SDR is a mandatory part of work-up; the same skull characteristics also generate a skull score in the treatment software that flags elements likely to overheat.

4.Treating the low-SDR patient

Patients with SDR below 0.40 can still be treated, and increasingly are, but the strategy changes. A reported approach for low-SDR tremor patients is to minimize the number of low-yield alignment sonications and move to high-energy treatment sonications early (in one series, treatment sonications exceeding ~36,000 J), which produced lesion volumes and tremor improvement comparable to high-SDR patients without a significant increase in adverse events, and shortened the session (Nishida et al., 2024, treating down to an SDR threshold of 0.35). The trade-off is that the energy and discomfort burden is front-loaded, and the margin for error is thinner. The decision to treat a low-SDR patient is a deliberate one, made with the patient informed that the chance of an underpowered lesion and of intraprocedural discomfort is higher.

5.The sonication ladder: alignment, verification, ablation

A treatment is not one exposure but a graded series of sonications, each a few seconds long, separated by cooling intervals. The energy is escalated deliberately through three functional stages:

• Alignment / geometric verification — very low-energy sonications producing a sub-therapeutic temperature rise (roughly 40–43°C), used to confirm that the heated focal spot actually coincides with the planned target on MR thermometry, and to correct any geometric offset before any tissue is harmed.
• Verification / neurologic test — intermediate-energy sonications that warm the target to roughly 46–50°C, producing a reversible functional effect. The awake patient is examined: tremor should improve and no adverse effect (paresthesia, dysarthria, ataxia, weakness) should appear. This reversible test phase — impossible with radiofrequency or radiosurgery — is the safety signature of MRgFUS, allowing the target to be adjusted before committing to a permanent lesion.
• Ablation — once the test confirms benefit without deficit, power is increased to drive the peak temperature to roughly 54–60°C, the range that produces irreversible protein denaturation and coagulation necrosis. Sustained temperatures at the upper end create the definitive lesion.

6.Loss of efficiency per sonication — and why power must climb

A central practical reality of the procedure is that heating becomes progressively less efficient as treatment proceeds. Heating efficiency — the peak temperature rise achieved per unit of delivered acoustic energy — declines over successive sonications. Two mechanisms drive this. First, the skull and scalp absorb a fraction of every sonication and accumulate heat; transient heating of the bone alters its acoustic properties, increasing beam aberration and enlarging and blurring the focal spot so that the same energy is spread over a larger volume and produces a smaller peak temperature rise. Second, low SDR compounds the problem from the outset, because a poorly transmitting skull starts with low efficiency and has less headroom.

The practical consequence is that the operator must increase the acoustic energy (power × time) of each successive sonication to reach the next temperature milestone — the target that warmed to 50°C at one power may need substantially more to reach 55°C, and more again to reach 58°C. This is why low-SDR planning front-loads high-energy sonications while the skull is still "cold" and efficiency is highest, and why minimizing wasted alignment sonications matters.

This escalation cannot continue indefinitely. There is a hard energy ceiling: the device has a maximum deliverable energy, and beyond a point further power risks scalp burns, off-target heating, and acoustic cavitation (the violent collapse of microbubbles, which the system is engineered to stay below). When a skull is inefficient enough that the focal temperature plateaus below the ablative range even at maximum tolerated energy, the lesion cannot be completed — the dominant mechanism of MRgFUS treatment failure, and the reason a low-SDR skull is a genuine contraindication rather than an inconvenience.

7.What to expect, and the adverse-event profile

Tremor improvement is typically immediate and visible on the table during the verification phase, which is one of the procedure's distinctive features. The most common side effects relate to the target's neighbors: gait or limb ataxia, paresthesia (often perioral or in the hand), and, less often, dysarthria or hand weakness. In the pivotal trial most adverse events were mild to moderate, and the majority of sensory and gait disturbances resolved or improved over weeks to months, though a minority persist. Because the lesion is permanent, persistent ataxia or paresthesia cannot be reversed — the central counseling point that distinguishes ablation from DBS. There is no implanted hardware, no programming, and no battery; the trade is durability and adjustability (DBS) against incisionless simplicity and an on-table result (MRgFUS).